List of Excipients in Branded Drug GOOD SENSE MICONAZOLE 7

Generic Drugs Containing GOOD SENSE MICONAZOLE 7

Company	Ingredient	NDC	Excipient
L Perrigo Company	miconazole nitrate	0113-0214	BENZOIC ACID
L Perrigo Company	miconazole nitrate	0113-0214	BUTYLATED HYDROXYANISOLE
L Perrigo Company	miconazole nitrate	0113-0214	GLYCERYL MONOSTEARATE

What are the Most Frequently-Used Excipients in GOOD SENSE MICONAZOLE 7?

# Of NDCs	Excipient
2	BENZOIC ACID
2	BUTYLATED HYDROXYANISOLE
2	GLYCERYL MONOSTEARATE

GoodSense Miconazole 7 Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

GoodSense Miconazole 7 is an OTC vaginal cream containing miconazole nitrate 2% for a seven-day treatment course of vaginal yeast infection. Its commercial opportunity is primarily in cost-efficient formulation, applicator design, private-label distribution, packaging differentiation, and adjacent vaginal-health products. The product has limited protection from drug patents because miconazole is an established generic active ingredient marketed under the FDA OTC monograph pathway.

What is GoodSense Miconazole 7?

GoodSense Miconazole 7 is a vaginal cream containing 2% miconazole nitrate. The product is used intravaginally once daily for seven consecutive days, generally with prefilled disposable applicators. GoodSense is a private-label OTC brand associated with retail pharmacy distribution.

Attribute	Product profile
Brand	GoodSense Miconazole 7
Active ingredient	Miconazole nitrate 2%
Dosage form	Vaginal cream
Course	Seven days
Route	Intravaginal
Therapeutic category	OTC vaginal antifungal
Primary indication	Vaginal yeast infection
Regulatory route	FDA OTC monograph pathway
Likely commercial format	Multi-dose tube with disposable applicators or prefilled applicators
Biosimilar relevance	None
Orange Book relevance	Generally limited because the product is an OTC monograph drug rather than an NDA product

Miconazole nitrate is an imidazole antifungal that inhibits fungal ergosterol synthesis. The formulation must deliver the active ingredient locally while maintaining acceptable spreadability, retention, leakage control, microbiological quality, and patient comfort.

What excipients are used in GoodSense Miconazole 7?

The marketed formulation is based on a conventional oil-in-water vaginal cream system. Public labeling for miconazole nitrate 2% vaginal cream products identifies excipients commonly including mineral oil, purified water, stearyl alcohol, polysorbate 60, glyceryl monostearate, PEG stearate, xanthan gum, and benzoic acid.[1]

Exact excipient composition can vary by manufacturer, product code, and manufacturing site. A commercial formulation strategy should therefore treat the current GoodSense composition as a benchmark rather than assume that all miconazole 7 products have identical inactive ingredients.

Functional role of the principal excipients

Excipient	Formulation function	Commercial importance
Mineral oil	Emollient, oil-phase vehicle, lubricity	Supports cream feel and vaginal application
Stearyl alcohol	Consistency agent and co-emulsifier	Controls viscosity and physical stability
Polysorbate 60	Nonionic surfactant and emulsifier	Supports oil-water dispersion
Glyceryl monostearate	Emulsifier and bodying agent	Contributes to cream structure
PEG stearate	Emulsification and texture modification	Helps stabilize the cream matrix
Xanthan gum	Rheology modifier and suspending agent	Improves viscosity and reduces phase separation
Benzoic acid	Preservative and pH-control contributor	Supports microbiological quality
Purified water	Continuous aqueous phase	Enables vaginal cream delivery

The formulation is designed around local delivery rather than systemic absorption. The excipients must preserve miconazole uniformity throughout the product shelf life and maintain a reproducible dose from each applicator.

How should the excipient system be optimized?

The main optimization targets are vaginal retention, low leakage, patient comfort, active-ingredient uniformity, preservative performance, and compatibility with the applicator and packaging.

Emulsion structure

Miconazole nitrate has limited water solubility. A structured cream can hold the active in a dispersed or partially solubilized state while providing acceptable spreading. The oil phase contributes lubrication and residence time. The aqueous phase reduces excessive greasiness and improves washability.

A developer evaluating a competing formulation should characterize:

• Droplet-size distribution
• Miconazole particle size and polymorphic form
• Cream viscosity across shear rates
• Yield stress
• Phase separation after accelerated storage
• Active-content uniformity
• Applicator dose delivery
• Residual product in the tube or applicator

The most commercially useful formulation is not necessarily the one with the highest viscosity. Excessive viscosity can reduce applicator emptying, create dosing variability, and increase patient dissatisfaction.

Rheology and leakage control

Vaginal creams face a tradeoff between retention and discharge. Xanthan gum and fatty alcohols can increase structure and reduce immediate leakage, but high levels can create a heavy or tacky feel.

A differentiated product could use a controlled-yield-stress cream that:

1. Flows under applicator pressure.
2. Spreads at body temperature.
3. Recovers viscosity after administration.
4. Limits rapid leakage during movement.
5. Remains removable during normal hygiene.

This area may support formulation know-how, process controls, or patentable combinations if the formulation produces measurable performance advantages. The active ingredient itself is unlikely to provide meaningful exclusivity.

Preservative and pH strategy

Benzoic acid is a conventional preservative choice for acidic topical and vaginal formulations. The formulation should maintain a pH compatible with preservative activity, product stability, and vaginal tolerability.

Commercial development should assess:

• Antimicrobial effectiveness
• Preservative concentration over shelf life
• pH drift
• Interaction between preservative and surfactants
• Container or applicator adsorption
• Local irritation potential
• Compatibility with vaginal microbiota

Preservative reduction or preservative-free packaging may create a marketable distinction, but it can increase microbiological-control requirements. A single-dose or unit-dose architecture may support a lower-preservative strategy if supported by stability and microbiological data.

What formulation patents protect miconazole vaginal cream?

Miconazole vaginal cream is generally a low-barrier generic formulation category. The core active ingredient and basic 2% cream presentation are mature technologies. The principal competitive barriers are regulatory compliance, manufacturing consistency, supply reliability, packaging, and retail access.

Potentially protectable areas include:

• A specific emulsion architecture
• A narrow excipient concentration range
• Improved miconazole particle-size distribution
• Reduced leakage after intravaginal administration
• Enhanced active-ingredient release
• Preservative-free unit-dose packaging
• A low-irritation formulation
• Compatibility with an applicator or delivery device
• A formulation with improved stability under temperature excursions
• A combined antifungal and vaginal-microbiome support product

A patent claim must be supported by measurable technical results. Broad claims covering "miconazole in a vaginal cream" would face substantial validity and prior-art risk because comparable products have been marketed for decades.

What is the FDA regulatory status of GoodSense Miconazole 7?

Miconazole nitrate vaginal products are regulated as OTC vaginal antifungal products under FDA requirements for vaginal drug products. The relevant regulatory framework is 21 C.F.R. Part 333, including provisions governing antifungal active ingredients and labeling.[2]

Miconazole nitrate at a 2% concentration in a seven-day vaginal cream is a recognized OTC product format. The product must comply with applicable requirements for:

• Active ingredient identity and concentration
• Indications and warnings
• Directions for use
• Tamper-evident packaging
• Manufacturing controls
• Stability
• Microbiological quality
• Drug Facts labeling
• Applicator performance and packaging integrity

The product is not dependent on FDA approval of a novel molecular entity. Its commercial status is therefore more closely tied to monograph compliance and product-specific manufacturing quality than to an NDA lifecycle.

Does GoodSense Miconazole 7 have Orange Book exclusivity?

GoodSense Miconazole 7 is generally not expected to have meaningful Orange Book exclusivity. OTC monograph products are not comparable to prescription NDA products with listed patents, pediatric exclusivity, or statutory new-drug exclusivity.

An OTC monograph-compliant miconazole product typically has:

• No Paragraph IV litigation pathway comparable to an ANDA product
• No five-year NCE exclusivity
• No three-year clinical-investigation exclusivity
• No expected Orange Book patent estate protecting the marketed product
• No biosimilar or interchangeable-biologic issue

The principal IP assets are likely trademarks, packaging design, private-label relationships, manufacturing know-how, and any formulation or device patents separately developed by the manufacturer.

When does GoodSense Miconazole 7 lose exclusivity?

GoodSense Miconazole 7 does not have a conventional prescription-drug exclusivity date. Its market protection is functional and commercial rather than statutory.

Protection type	Expected relevance
NCE exclusivity	None
NDA exclusivity	None expected
Pediatric exclusivity	None expected
Orange Book patent term	Generally not applicable
Paragraph IV exposure	Generally not applicable
OTC monograph status	Allows compliant competitors to enter
Trademark protection	Applies to GoodSense branding
Trade dress	May protect packaging presentation
Supplier know-how	May protect process and cost position
Retail distribution	Can create practical market access advantages

Competitors can generally enter with a compliant miconazole nitrate 2% vaginal cream without waiting for expiration of a product-specific patent. This makes price, shelf placement, consumer trust, and supply execution central to market performance.

What commercial opportunities exist for excipient innovation?

1. Low-leakage vaginal cream

A higher-retention cream could compete on user experience. The formulation opportunity is to improve residence time without producing an excessively thick or greasy product.

Commercial claims would need to be supported by appropriate laboratory, ex vivo, or clinical evidence. Possible positioning includes improved comfort, reduced leakage, and easier nighttime use.

2. Preservative-reduced or preservative-free product

A unit-dose, hermetically sealed presentation could reduce dependence on preservatives. This may appeal to consumers who associate preservatives with irritation.

The commercial tradeoff is higher packaging cost and potentially lower manufacturing flexibility. The opportunity is strongest in premium retail, e-commerce, and sensitive-skin segments.

3. Cleaner excipient profile

A product could be positioned around a simplified excipient system, fewer surfactants, or avoidance of selected excipients perceived as irritating. "Clean-label" positioning must remain consistent with FDA OTC labeling rules and cannot imply superior efficacy without evidence.

4. Improved applicator system

The applicator is a major source of user experience differentiation. Opportunities include:

• Graduated dose control
• Reduced residual cream
• Rounded, low-irritation insertion geometry
• Easier one-handed loading
• Applicator materials with lower product adsorption
• Recyclable or reduced-plastic components
• Tamper-evident unit-dose packaging

An applicator patent may provide stronger practical differentiation than a conventional cream composition patent.

5. Thermally robust formulation

Retail and e-commerce distribution can expose products to temperature excursions. A formulation with improved resistance to phase separation, viscosity drift, and active crystallization could reduce returns and distribution losses.

Useful development targets include stability after freeze-thaw cycles, high-temperature storage, shipping vibration, and repeated tube opening.

6. Value packs and channel-specific packaging

The seven-day regimen supports multiple commercial formats:

Format	Target channel	Opportunity
Standard tube plus applicators	Mass retail and pharmacy	Lowest-cost broad distribution
Prefilled applicators	Convenience and e-commerce	Simplifies administration
Travel pack	Convenience retail	Portable, discreet packaging
Sensitive-skin version	Premium OTC	Excipient differentiation
Multi-pack	Household or recurring users	Lower per-course cost
Subscription format	E-commerce	Replenishment and discreet delivery

The core product is highly price-sensitive. Packaging and fulfillment improvements should therefore be evaluated against unit economics rather than treated as standalone premium features.

How strong is the patent estate for GoodSense Miconazole 7?

The patent estate is likely weak at the product level and stronger in adjacent technical areas. The active ingredient is mature, the dosage form is conventional, and OTC monograph entry reduces the value of product-specific exclusivity.

Patent-strength assessment

Asset category	Relative strength	Reason
Miconazole composition patent	Low	Mature active ingredient
Conventional 2% vaginal cream	Low	Extensive prior art and market history
Specific excipient range	Moderate	Requires unexpected technical effect
Low-leakage rheology system	Moderate	Strength depends on comparative data
Preservative-free unit dose	Moderate	Packaging and microbiological data are critical
Applicator design	Moderate to high	Device claims may be differentiated
Manufacturing process	Moderate	Can protect reproducibility and scale-up
Brand and trade dress	Moderate	Supports market identity, not formulation exclusivity
Supplier agreements	Commercially important	May restrict access to qualified materials

A defensible patent program would focus on a defined performance problem, such as controlled retention, low active crystallization, or improved applicator emptying. Broad ingredient lists are less likely to create durable protection.

Which companies are challenging GoodSense Miconazole 7?

The competitive field includes private-label manufacturers, pharmacy brands, mass-retail brands, and branded products such as Monistat. Generic miconazole vaginal cream products can compete through the same OTC regulatory framework.

Relevant competitor categories include:

• Retailer-controlled private labels
• Generic OTC manufacturers
• Branded vaginal antifungal companies
• Online pharmacy and direct-to-consumer sellers
• Combination vaginal-health brands

Competition generally occurs without Paragraph IV litigation because the product category is not built around an innovator NDA with Orange Book-listed patents. The commercial challenge is shelf access and customer acquisition.

What licensing deals could support commercial expansion?

Licensing opportunities are more likely to involve manufacturing, packaging, retail distribution, or regional commercialization than core active-ingredient rights.

Potential transaction structures include:

Deal type	Strategic purpose
Contract manufacturing agreement	Reduce capital expenditure and accelerate launch
Private-label supply agreement	Secure retailer volume
Regional distribution license	Expand into new geographic markets
Applicator technology license	Differentiate administration
Excipient or emulsion technology license	Improve retention or stability
Co-branding agreement	Increase consumer recognition
E-commerce fulfillment partnership	Improve discreet delivery
Packaging sustainability license	Reduce plastic or improve recyclability

The highest-value licensing asset would likely be a validated formulation or delivery system that demonstrates better retention, comfort, stability, or dose delivery than conventional miconazole cream.

What generic launch risks exist?

Generic and private-label launch risk is high because entry barriers are modest. The principal risks are operational and commercial.

Manufacturing and supply risks

Miconazole nitrate quality can affect particle-size distribution, suspension uniformity, and release behavior. Excipient variability can alter viscosity and emulsion stability. Supplier qualification is therefore important for:

• Miconazole particle characteristics
• Mineral oil grade
• Fatty alcohol purity
• Surfactant quality
• Xanthan gum rheology
• Preservative consistency
• Applicator polymer composition

A dual-source strategy can reduce supply interruption risk, but changing excipient suppliers may require comparability work and updated stability data.

Regulatory and quality risks

Common failure points include:

• Inadequate antimicrobial effectiveness
• Inconsistent active-content uniformity
• Phase separation
• Applicator dose variability
• Labeling deviations
• Inadequate stability under shipping conditions
• Container-closure integrity problems
• Excessive microbiological counts

For a low-cost OTC product, a recall can eliminate the economic benefit of small formulation savings.

Commercial risks

Retailers may prioritize existing private-label suppliers and established branded products. A new entrant must compete on landed cost, fill rate, packaging, consumer ratings, and retailer margin.

A formulation premium is difficult to sustain unless the product has a clear consumer-facing benefit. The strongest opportunities are likely in channels where privacy, convenience, and sensitivity concerns carry more value than the lowest shelf price.

How does GoodSense Miconazole 7 compare with other vaginal antifungal products?

Product type	Active ingredient	Typical treatment duration	Main differentiation
Miconazole 7	Miconazole nitrate 2%	7 days	Lower-intensity daily regimen and established generic format
Miconazole 3	Miconazole nitrate 4%	3 days	Shorter course
Miconazole 1	Miconazole nitrate 1,200 mg dose	1 day	Convenience
Clotrimazole products	Clotrimazole	Varies	Alternative azole active
Tioconazole products	Tioconazole	Often 1 day	Single-dose convenience
Prescription azoles	Various	Varies	Clinician-directed therapy

GoodSense Miconazole 7 competes on established efficacy, broad availability, and potentially lower price. Its main disadvantage is the seven-day administration period compared with one-day and three-day products.

An excipient strategy that improves comfort and reduces leakage could help offset the longer treatment course. A reformulated product would still need to preserve the expected dose, labeling, and OTC regulatory profile.

What geographic coverage and manufacturing barriers apply?

The product category is strongest in the United States because GoodSense is a U.S. retail private-label brand and the formulation aligns with the FDA OTC framework. International expansion would require country-specific review of:

• Miconazole vaginal product classification
• Permitted excipients
• Preservative requirements
• Labeling language
• Applicator rules
• Medical-device or drug combination requirements
• Local pharmacopoeial standards
• Import and manufacturing controls

Manufacturing barriers are moderate. The cream can be produced using conventional emulsion equipment, but scale-up requires control of mixing order, temperature profile, homogenization, cooling rate, deaeration, and filling conditions.

The most difficult process variables are usually emulsion consistency, active dispersion, viscosity control, and reliable filling into tubes or applicators.

Key Takeaways

• GoodSense Miconazole 7 is an OTC vaginal cream containing miconazole nitrate 2% for a seven-day regimen.
• Its excipient system is a conventional aqueous cream built around mineral oil, fatty alcohols, surfactants, PEG stearate, xanthan gum, purified water, and benzoic acid.
• The product is unlikely to have meaningful NDA exclusivity, Orange Book protection, or Paragraph IV litigation exposure.
• The strongest commercial opportunities are low-leakage formulations, improved applicators, preservative-reduced packaging, thermal stability, and sensitive-skin positioning.
• Broad composition patents are likely weak because miconazole vaginal cream is a mature category.
• Narrow formulation, process, and device claims can have value if supported by comparative performance data.
• Retail access, manufacturing cost, supply reliability, and packaging execution are more important than active-ingredient exclusivity.
• A differentiated product should target a measurable consumer benefit while retaining the cost advantages of the OTC monograph pathway.

FAQs

Is GoodSense Miconazole 7 a generic drug?

Yes. It is an OTC miconazole nitrate vaginal product sold under a private-label brand. It competes with branded and generic miconazole products.

Can a competitor launch a miconazole 2% vaginal cream without a Paragraph IV challenge?

Generally, yes, if the product complies with applicable FDA OTC requirements. Paragraph IV certification is primarily associated with ANDAs referencing patents listed for approved prescription or nonprescription NDA products.

What is the best excipient opportunity for a premium miconazole product?

A controlled-retention cream with lower leakage and improved comfort is among the strongest opportunities. The product must demonstrate dose uniformity, stability, microbiological quality, and acceptable local tolerability.

Can a preservative-free miconazole vaginal cream be commercialized?

Potentially, but the product would need a suitable packaging and microbiological-control strategy. Unit-dose or prefilled applicator packaging could support this approach.

Does the applicator create patent value?

Yes. A novel applicator with improved dose delivery, lower residual product, reduced irritation, or easier administration may offer stronger patent protection than a conventional miconazole cream composition.

References

1. National Library of Medicine. (n.d.). Miconazole nitrate 2% vaginal cream product labeling. DailyMed. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (2024). 21 C.F.R. Part 333, Subpart D: Antifungal drug products for over-the-counter human use. Electronic Code of Federal Regulations. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-333

3. U.S. Food and Drug Administration. (2020). Over-the-counter monograph reform and regulation of nonprescription drug products. Federal Register. https://www.federalregister.gov/

4. U.S. Food and Drug Administration. (2024). Nonprescription drug products and OTC monograph system. https://www.fda.gov/drugs/over-counter-otc-nonprescription-medicines